Stuart Therapeutics Announces Start of Patient Enrollment in its Phase 2 Clinical Trial of ST-100 for Dry Eye Disease,

Stuart Therapeutics, Inc. (” Stuart “), a clinical stage biopharmaceutical company conducting research and development of unique peptide therapeutics for ophthalmic diseases, today announced the start …, Stuart Therapeutics, Inc. (” Stuart “), a clinical stage biopharmaceutical company conducting research and development of unique peptide therapeutics for ophthalmic diseases, today announced the start …, Read More

Scroll to Top